ASP Isotopes Targets $300M EBITDA by 2031 as Commercial Shipments Begin
Event summary
- ASP Isotopes expects first commercial shipments of Silicon-28, Carbon-14, and Ytterbium-176 in 2026.
- Helium Phase 1 nameplate capacity targeted for Q3 2026, with Phase 2 expected to produce 34,000 GJ/day of LNG.
- Company aims for $300M+ EBITDA by 2031, with $333M in cash and marketable securities as of December 31, 2025.
- Radiopharmaceutical revenues projected to double to $10M in 2026, driven by U.S. acquisitions.
The big picture
ASP Isotopes is positioning itself as a critical supplier in three high-growth sectors: nuclear medicine, advanced semiconductors, and energy. The company's ability to scale production across multiple isotopes while maintaining financial discipline will determine its long-term viability in an increasingly competitive landscape. With $333M in cash reserves and strategic acquisitions in the U.S., ASP is expanding its footprint while targeting a $300M EBITDA milestone by 2031.
What we're watching
- Execution Risk
- Whether ASP can meet its 2026 commercial shipment targets across multiple isotopes.
- Market Demand
- How semiconductor and nuclear medicine industries will absorb ASP's scaled isotope production.
- Financial Discipline
- The pace at which ASP can transition from high cash burn to profitability.
Related topics